LLY ROA | ELI LILLY AND COMPANY

ELI LILLY & Co ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

ELI LILLY & Co roa for the quarter ending 2026-06-30 was 18.77%, a 37.29% increase year-over-year.
ELI LILLY & Co roa for the quarter ending 2026-03-31 was 21.68%, a 74.52% increase year-over-year.
ELI LILLY & Co roa for the quarter ending 2025-12-31 was 18.35%, a 36.40% increase year-over-year.
ELI LILLY & Co roa for the quarter ending 2025-09-30 was 16.02%, a 44.72% increase year-over-year.
ELI LILLY & Co roa for fiscal 2025 was 18.35%, a 36.40% increase from fiscal 2024.
ELI LILLY & Co roa for fiscal 2024 was 13.45%, a 64.33% increase from fiscal 2023.
ELI LILLY & Co roa for fiscal 2023 was 8.19%, a 35.12% decline from fiscal 2022.
ELI LILLY & Co roa for fiscal 2022 was 12.62%, a 10.33% increase from fiscal 2021.

Available history: 2008-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical ROA

Date	ROA	Net income 12 month	Net income 3 month	Total assets
2026-06-30	18.77%	$26.71B	$7.09B	$142.28B
2026-03-31	21.68%	$25.28B	$7.40B	$116.58B
2025-12-31	18.35%	$20.64B	$6.64B	$112.48B
2025-09-30	16.02%	$18.41B	$5.58B	$114.94B
2025-06-30	13.67%	$13.8B	$5.66B	$100.92B
2025-03-31	12.42%	$11.11B	$2.76B	$89.39B
2024-12-31	13.45%	$10.59B	$4.41B	$78.72B
2024-09-30	11.07%	$8.37B	$970.30M	$75.61B
2024-06-30	10.21%	$7.34B	$2.97B	$71.87B
2024-03-31	9.60%	$6.14B	$2.24B	$63.94B
2023-12-31	8.19%	$5.24B	$2.19B	$64.01B
2023-09-30	8.61%	$4.99B	-$57.40M	$57.92B
2023-06-30	11.85%	$6.5B	$1.76B	$54.81B
2023-03-31	10.70%	$5.69B	$1.34B	$53.16B
2022-12-31	12.62%	$6.24B	$1.94B	$49.49B
2022-09-30	12.71%	$6.03B	$1.45B	$47.46B
2022-06-30	12.09%	$5.69B	$952.50M	$47.06B
2022-03-31	13.06%	$6.13B	$1.90B	$46.92B
2021-12-31	11.44%	$5.58B	$1.73B	$48.81B
2021-09-30	12.39%	$5.97B	$1.11B	$48.19B
2021-06-30	12.70%	$6.07B	$1.39B	$47.81B
2021-03-31	13.01%	$6.09B	$1.36B	$46.84B
2020-12-31	13.28%	$6.19B	$2.12B	$46.63B
2020-09-30	12.68%	$5.57B	$1.21B	$43.95B
2020-06-30	13.39%	$5.62B	$1.41B	$41.97B
2020-03-31	13.46%	$5.53B	$1.46B	$41.1B
2019-12-31	21.17%	$8.32B	$1.50B	$39.29B
2019-09-30	20.97%	$7.95B	$1.25B	$37.89B
2019-06-30	20.28%	$7.84B	$1.33B	$38.67B
2019-03-31	16.46%	$6.26B	$4.24B	$38.01B
2018-12-31	7.36%	$3.23B	$1.13B	$43.91B
2018-09-30	1.01%	$450.1M	$1.15B	$44.63B
2018-06-30	-0.34%	-$143.8M	-$259.90M	$42.36B
2018-03-31	2.53%	$1.12B	$1.22B	$44.36B
2017-12-31	-0.45%	-$204.1M	-$1.66B	$44.98B
2017-09-30	5.17%	$2.22B	$555.60M	$43.01B
2017-06-30	5.98%	$2.45B	$1.01B	$40.95B
2017-03-31	5.81%	$2.19B	-$110.80M	$37.62B
2016-12-31	7.05%	$2.74B	$771.80M	$38.81B
2016-09-30	6.50%	$2.44B	$778.00M	$37.59B
2016-06-30	6.76%	$2.47B	$747.70M	$36.48B
2016-03-31	6.68%	$2.32B	$440.10M	$34.69B
2015-12-31	6.77%	$2.41B	$478.40M	$35.57B
2015-09-30	6.50%	$2.36B	$799.70M	$36.3B
2015-06-30	5.71%	$2.06B	$600.80M	$36.04B
2015-03-31	6.15%	$2.19B	$529.50M	$35.65B
2014-12-31	6.58%	$2.39B	$428.50M	$36.31B
2014-09-30	7.76%	$2.69B	$500.60M	$34.65B
2014-06-30	9.69%	$3.39B	$733.50M	$35.02B
2014-03-31	11.12%	$3.86B	$727.90M	$34.76B
2013-12-31	13.29%	$4.68B	$727.50M	$35.25B
2013-09-30	14.09%	$4.78B	$1.20B	$33.97B
2013-06-30	14.77%	$4.91B	$1.21B	$33.23B
2013-03-31	14.32%	$4.63B	$1.55B	$32.3B
2012-12-31	11.89%	$4.09B	$827.20M	$34.4B
2012-09-30	12.00%	$4.12B	$1.33B	$34.32B
2012-06-30	12.67%	$4.03B	$923.60M	$31.81B
2012-03-31	13.35%	$4.3B	$1.01B	$32.24B
2011-12-31	12.92%	$4.35B	$858.20M	$33.66B
2011-09-30	14.10%	$4.66B	$1.24B	$33.04B
2011-06-30	14.42%	$4.73B	$1.20B	$32.78B
2011-03-31	15.39%	$4.88B	$1.06B	$31.7B
2010-12-31	16.35%	$5.07B	$1.17B	$31B
2010-09-30	16.10%	$4.82B	$1.30B	$29.9B
2010-06-30	16.07%	$4.45B	$1.35B	$27.72B
2010-03-31	15.68%	$4.26B	$1.25B	$27.2B
2009-12-31	15.76%	$4.33B	$915.40M	$27.46B
2009-09-30	-0.80%	-$216M	$941.80M	$27.13B
2009-06-30	-6.03%	-$1.62B	$1.16B	$26.93B

Annual ROA

Date	ROA	Net income 12 month	Total assets
2025-12-31	18.35%	$20.64B	$112.48B
2024-12-31	13.45%	$10.59B	$78.72B
2023-12-31	8.19%	$5.24B	$64.01B
2022-12-31	12.62%	$6.24B	$49.49B
2021-12-31	11.44%	$5.58B	$48.81B
2020-12-31	13.28%	$6.19B	$46.63B
2019-12-31	21.17%	$8.32B	$39.29B
2018-12-31	7.36%	$3.23B	$43.91B
2017-12-31	-0.45%	-$204.1M	$44.98B
2016-12-31	7.05%	$2.74B	$38.81B
2015-12-31	6.77%	$2.41B	$35.57B
2014-12-31	6.58%	$2.39B	$36.31B
2013-12-31	13.29%	$4.68B	$35.25B
2012-12-31	11.89%	$4.09B	$34.4B
2011-12-31	12.92%	$4.35B	$33.66B
2010-12-31	16.35%	$5.07B	$31B
2009-12-31	15.76%	$4.33B	$27.46B
2008-12-31	-7.09%	-$2.07B	$29.21B

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Akari Therapeutics Plc (AKTX)		$1,527.991B	-47,921.42
JOHNSON & JOHNSON (JNJ)	United States	$652.528B	29.10
AbbVie Inc. (ABBV)	United States	$468.180B	70.37
Merck & Co., Inc. (MRK)	United States	$365.215B	99.96
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
PFIZER INC (PFE)	United States	$162.042B	31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94